AtriCure (ATRC 10.27%), a medical device company specializing in cardiac surgical technologies, delivered its earnings release on July 29, 2025, reporting results that outpaced Wall Street consensus estimates. The company posted revenue of $136.1 million (GAAP), ahead of the $130.2 million analyst estimate (GAAP), and a non-GAAP loss per share of $(0.02), a substantial improvement from $(0.17) a year ago and handily above expectations (non-GAAP). The period saw strong momentum in open ablation, appendage ma ...